Chlorpromazine(Wintermine) Veterinary Grade API is the hydrochloride salt of 2-chloro-10-[3-(dimethylamino)propyl]phenothiazine, CAS 69-09-0, molecular formula C₁₇H₁₉ClN₂S·HCl, molar mass 355.33 g/mol. The material is supplied as a white to off-white crystalline powder in opaque, double low-density-polyethylene-lined fiber drums. The Wintermine designation identifies the originator-era model; the veterinary-grade qualification is a regulatory and supply-chain attribute rather than a separate chemical identity. The product is released under ICH Q7 GMP for active pharmaceutical ingredients, with batch production records, stability data, and traceability documentation. It is qualified for tablet, capsule, powder, granule, premix, oral solution, and injectable solution manufacture when the necessary microbiological controls are applied. The phenothiazine ring is photolabile and electron-rich; storage must be protected from light, and contact with strong oxidizing agents must be avoided because chlorpromazine sulfoxide and colored oxidation products form readily.

In aqueous systems, chlorpromazine hydrochloride is freely soluble in purified water, and the tertiary amine side chain has a pK_a near 9.3. The solution pH of the salt is typically 4.0–5.5. Above pH 6.5, free base partitioning increases and precipitation risk rises; oxidation also accelerates as the pH approaches the pK_a. This boundary is critical for injectable, oral solution, and wet granulation operations. The pH-dependent solubility profile differentiates chlorpromazine from neutral or weakly acidic veterinary APIs, for which pH drift during manufacture is less consequential.

The material is manufactured under ICH Q7 and EU GMP Part II. Batch certificates of analysis report actual results for assay, related substances, residual solvents, elemental impurities, and, when specified, bacterial endotoxins. The stability program follows VICH GL3 and includes long-term testing at 25 °C/60% RH and accelerated testing at 40 °C/75% RH. The retest period is assigned from long-term data; published data for this specific veterinary-grade configuration is limited, but the degradation behavior of chlorpromazine hydrochloride is controlled by light, moisture, and oxidant exposure.

Compendial Release Parameters and the Veterinary GMP Specification Matrix

Release specifications are derived from current pharmacopoeial monographs for chlorpromazine hydrochloride and from veterinary guidance. Identification is confirmed by infrared absorption spectrophotometry against a qualified reference standard and by HPLC retention time. The assay is expressed as C₁₇H₁₉ClN₂S·HCl on the dried basis. Related substances are determined by a stability-indicating HPLC method; the method is capable of resolving chlorpromazine sulfoxide and other phenothiazine-related impurities. The table presents a representative control matrix for solid oral and injectable applications.

Residual solvent control uses VICH GL18 and USP <467>; class 2 solvents such as dichloromethane and toluene have limits of 600 ppm and 890 ppm respectively when present in the synthesis route. Elemental impurities are controlled according to ICH Q3D, with the final permitted daily exposure calculated from the maximum daily dose in the target species. The veterinary-grade release package therefore differs from research-grade chlorpromazine by including these route-specific limits and the associated analytical documentation.

The stability-indicating HPLC method uses a reversed-phase C18 column and ultraviolet detection near 254 nm; the mobile phase is typically a buffered acetonitrile–phosphate system. Chlorpromazine sulfoxide, a primary photodegradant, elutes before the active peak; method resolution between chlorpromazine and its sulfoxide should be not less than 2.0. The limit of quantitation for unspecified impurities is typically 0.05% by area. These parameters ensure that minor degradation during milling, drying, or sterilization is detected before batch release.

No compendial monograph assigns a harmonized particle size specification for chlorpromazine hydrochloride, but particle size distribution becomes a process-critical attribute when the API is used in low-dose dry blends. Air-jet milling and pin-milling yield different surface energies and flow properties. A target D₅₀ of 20–40 µm and D₉₀ ≤ 100 µm is common for direct compression and capsule filling. Laser diffraction is performed according to USP <429>. Particles below D₅₀ 10 µm increase electrostatic adhesion and may reduce flow, while particles above D₉₀ 180 µm create segregation potential in low-dose formulations. For premix intermediates, a larger particle size may reduce dusting, but final feed homogeneity must still be validated. The surface energy difference between chlorpromazine and excipients is more important than bulk density alone when designing a stable blend.

Chlorpromazine hydrochloride is crystalline; no therapeutically relevant polymorphic variation is documented in the current compendial monographs. However, milling can induce amorphous surface regions that increase hygroscopicity. The amorphous fraction may be monitored by differential scanning calorimetry or dynamic vapor sorption when particle size reduction is used. Manufacturers that mill under nitrogen and control mill feed rate limit amorphization and oxidative surface damage. This is a more important control for chlorpromazine than for simple inorganic veterinary APIs, because surface amorphous content can accelerate photodegradation and cause batch-to-batch color variation.

Why Is Particle Size Distribution a Boundary Condition for Solid Oral Dosage Uniformity?

Low-dose chlorpromazine tablets and capsules commonly contain 10 mg or 25 mg per unit. When the active fraction is less than 5% w/w, direct compression blends are segregation-sensitive. If the API D₉₀ exceeds about 100 µm, content uniformity under USP <905> can fail because coarse active particles distribute unevenly in bin blender discharge and in the feed frame of a rotary tablet press. Production-scale observations indicate that a D₅₀ below 40 µm reduces tablet-to-tablet assay variability when direct compression fillers such as spray-dried lactose monohydrate and microcrystalline cellulose are used. The forced feeder speed and fill depth may require adjustment when the API is micronized; excessive overfill can lead to densification and sticking. Capsule filling on dosator or tamping-pin machines requires similar particle size matching, particularly if the fill weight is below 150 mg. Blending time must be validated for each batch size because chlorpromazine hydrochloride can develop electrostatic charge under low-humidity conditions.

Where direct compression is not feasible because of flow or segregation risk, wet granulation is selected. Chlorpromazine hydrochloride shows acceptable chemical stability in acidic aqueous granulation fluid, but the granulation endpoint must prevent overgranulation and moisture retention. Drying is typically controlled with an inlet air temperature not exceeding 60 °C; final granule moisture is held below 2.0% w/w. These boundaries are tighter than those for many neutral APIs because residual moisture promotes hydrolysis and discoloration of the phenothiazine ring. At relative humidity above 60%, pre-drying of excipients is required before dry blending to prevent adherence to blender walls and to maintain acceptable flow through the compression hopper.

Injectable veterinary formulations containing chlorpromazine hydrochloride are manufactured as aqueous solutions, often at 25 mg/mL. Dissolution is performed in water for injection under a nitrogen purge; sodium metabisulfite or sodium sulfite is introduced as an oxygen scavenger at a concentration sufficient to maintain low headspace oxygen. The pH is adjusted to 4.5–5.5 with a suitable acid or buffer. The solution is passed through a 0.22 µm sterilizing-grade membrane filter into depyrogenated Type I glass vials. Because chlorpromazine can adsorb to polymeric materials, filter membrane and silicone tubing compatibility must be evaluated with product-specific spiking studies; assay loss across the filter should be less than 2.0% and the bubble point must remain intact after product filtration. The filled vials are protected from light during processing, inspection, and storage. Parenteral products are tested for visible particulates by USP <790>, subvisible particulates by USP <788>, and bacterial endotoxins by USP <85>. The endotoxin limit is derived from the maximum bolus dose in the target species, not assigned arbitrarily to the API.

When Sterile Filtration Becomes the Rate-Limiting Step for Injectable Chlorpromazine

If the formula cannot be terminally sterilized and aseptic filtration is the sole sterilization step, filtration parameters control the batch cycle. At pH values above 6.0, the fraction of unionized free base increases, which can reduce membrane flux and increase adsorptive losses onto the filter. Maintaining the solution below pH 5.5 and at 18–25 °C during filtration minimizes this effect. The filter compatibility study should measure flux decay, assay recovery, related substance formation, and post-filtration bubble point. Terminal sterilization at 121 °C for 15 minutes can be used only when the formulation includes an effective antioxidant and the headspace oxygen is held below 0.5%; otherwise the thermal cycle may generate discoloration and increase sulfoxide-related impurities above the release limit. Production-scale autoclave loads should be validated with heat-penetration studies and post-sterilization assay and related substance testing, because the temperature exposure is not uniform across the load. These injection-specific constraints are absent from solid oral dosage forms and represent the most sensitive processing window for phenothiazine APIs.

Oral powders and granules are prepared by trituration with lactose, glucose, or another compatible diluent and blended in a V-blender, ribbon mixer, or bin blender. Dust control is necessary because airborne chlorpromazine particles create cross-contamination and operator exposure risk. Premixes for medicated feed are usually manufactured as 1% or 5% w/w active intermediates on a suitable carrier; final feed incorporation is validated by thief sampling at defined points and by HPLC or stability-indicating assay. The inclusion rate determines the required number of samples and the acceptance limits; a low inclusion rate requires more intensive homogeneity testing than a high inclusion rate. In feed premix manufacture, the main process conflict is carryover and segregation at low inclusion rates. A ribbon mixer with a working capacity of 500 kg may require sampling at 10–20 points after a defined mixing time. The coefficient of variation for assay results should be below 5.0% for many veterinary premix applications. Cross-contamination limits for chlorpromazine in non-target feed are typically established by cleaning validation; the limit is based on the permitted daily exposure in the target species and analytical detection capability. Published data for specific mixer geometries are limited, so each mixer must be qualified with the actual formulation.

Oral solutions are compounded at acidic pH, packaged in amber polyethylene terephthalate or glass, and protected from ultraviolet light because photooxidation generates chlorpromazine sulfoxide and related colored degradation products. Long-term stability data for extemporaneous dilutions in non-compendial vehicles are limited; only formulations prepared in purified water or standard veterinary syrup bases under controlled pH should be considered validated. Forced degradation studies used to validate the impurity method include acid hydrolysis, base hydrolysis, oxidation with hydrogen peroxide, heat, and ultraviolet light. These studies are not part of routine release but support the stability-indicating nature of the analytical method.

In veterinary medicine, chlorpromazine hydrochloride is used as a tranquilizer, antiemetic, and preanesthetic adjunct in dogs, cats, and horses. The clinical effect arises from central dopaminergic and adrenergic receptor blockade, but the API specification does not determine clinical indications; it supports the manufacture of dosage forms that meet the requirements of the target market. The veterinary-grade material differs from analytical-grade chlorpromazine because it is released under a GMP quality system with batch production records, stability data, and controlled residual solvent and impurity profiles. It differs from human-grade material mainly in the regulatory package: the veterinary documentation follows VICH guidance, while the chemical purity requirements remain comparable. Technical or research-grade powder generally lacks the impurity, residual solvent, and documentation controls required for regulatory-compliant veterinary dosage forms. The product should be regarded as a starting raw material, not a sterile ready-to-inject solution; further processing and formal release testing are required for each finished dosage form.